All In Biotech

Free tool

FAERS Monitor: Danyelza

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 761171 or its brand name (Danyelza, Naxitamab-Gqgk). Reports on generic versions are filed under their own applications.

Reports

250

Serious

191

76% of reports

Hospitalization

86

Death reported

11

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • hypotension66
  • pain64
  • hypertension33
  • urticaria31
  • off label use29
  • pyrexia27
  • rash27
  • bronchospasm18
  • abdominal pain17
  • oxygen saturation decreased17
  • hypoxia15
  • tachycardia15
  • cough14
  • vomiting13
  • anaphylactic reaction11

Reports by year received

View as table
YearReports
20181
20191
20201
202147
202247
202326
202455
202549
202623

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,909 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
bronchospasmSignal18106.268.11,772
hypoxiaSignal1535.921.9475
hypotensionSignal6627.722.51,687
oxygen saturation decreasedSignal1725.516.1376
anaphylactic reactionSignal1116.89.4148
urticariaSignal3115.611.2411
tachycardiaSignal1514.28.7172
hypertensionSignal3313.19.5361
painSignal648.87.1446
pyrexiaSignal276.64.6124
abdominal painSignal176.13.969
rashSignal275.23.690
coughSignal144.22.531
off label useSignal292.82.033
vomitingSignal132.31.49

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.